{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:34:02Z","timestamp":1791462842238,"version":"4.3.4"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Pasireotide long-acting release (LAR), a long-acting somatostatin receptor ligand, has shown potential antitumour activity in somatotroph pituitary tumours, as indicated by increased T2-signal intensity on magnetic resonance imaging (MRI). However, long-term follow-up data on its effects are limited. This study aimed to evaluate the long-term antitumour effects of pasireotide and its impact on clinical outcomes in patients with acromegaly.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>The design is a retrospective cohort study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients from the previously published PAPE study were included. Over the course of 8 years, clinical outcomes, medication use, and tumour characteristics were assessed. T2-weighted MRI signals of tumours were analysed using grey matter as the reference region, and tumour volumes along with T2-intensity ratios (IRs) were calculated from all available scans.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Forty-four patients [57% male; median age 52 years (IQR 15)] were included. The median duration of pasireotide treatment was 31.0 months. From baseline to the 8-year follow-up, the median T2-IR increased from 1.03 to 1.56 (P &amp;lt; .001), indicating progressive cystic degeneration. Tumour volume significantly declined over time, with a median reduction from 1239 to 603\u2005mm\u00b3 (P = .005). Importantly, 12 patients (27.3%) experienced a reduction in medical acromegaly treatment, without the need for surgery or radiotherapy due to decreasing insulin-like growth factor 1 (IGF1) levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pasireotide appears to induce durable cystic degeneration in somatotroph tumours, with evidence suggesting sustained antitumor effects that may extend beyond treatment discontinuation. These findings support its potential for a broader therapeutic role, warranting validation in future prospective studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf194","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T05:21:56Z","timestamp":1758345716000},"page":"421-427","source":"Crossref","is-referenced-by-count":4,"title":["Long-term antitumour effects of pasireotide in acromegaly"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3168-8982","authenticated-orcid":false,"given":"Romy","family":"van der Groef","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section Endocrinology, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Pituitary Centre Rotterdam, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Veldhuijzen van Zanten","sequence":"additional","affiliation":[{"name":"Pituitary Centre Rotterdam, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Department of Radiology & Nuclear Medicine, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Brain Tumour Centre, Erasmus Medical Centre, Cancer Institute , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"van Beekveld","sequence":"additional","affiliation":[{"name":"Department of Radiology & Nuclear Medicine, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4045-4835","authenticated-orcid":false,"given":"Eskeatnaf","family":"Mulugeta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section Endocrinology, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Pituitary Centre Rotterdam, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Refardt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section Endocrinology, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Pituitary Centre Rotterdam, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian J C M M","family":"Neggers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section Endocrinology, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]},{"name":"Pituitary Centre Rotterdam, Erasmus Medical Centre , Rotterdam 3015 GD ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"issue":"4","key":"2025100609562455800_lvaf194-B1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"G\u00fcnther","year":"2018","journal-title":"Pharmacol Rev"},{"issue":"3","key":"2025100609562455800_lvaf194-B2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025100609562455800_lvaf194-B3","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025100609562455800_lvaf194-B4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"issue":"6","key":"2025100609562455800_lvaf194-B5","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1530\/EJE-19-0840","article-title":"T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly","volume":"182","author":"Coopmans","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025100609562455800_lvaf194-B6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2265.2011.04163.x","article-title":"Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly","volume":"76","author":"Fougner","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2025100609562455800_lvaf194-B7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S2213-8587(19)30113-5","article-title":"Potential antitumour activity of pasireotide on pituitary tumours in acromegaly","volume":"7","author":"Coopmans","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2025100609562455800_lvaf194-B8","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025100609562455800_lvaf194-B9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/00004728-199207000-00004","article-title":"Volume of pituitary macroadenomas: assessment by MRI","volume":"16","author":"Lundin","year":"1992","journal-title":"J Comput Assist Tomogr"},{"issue":"1","key":"2025100609562455800_lvaf194-B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1365-2265.2011.04286.x","article-title":"Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly","volume":"77","author":"Heck","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025100609562455800_lvaf194-B11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-18-0254","article-title":"MRI T2 signal intensity and tumor response in patients with GH-secreting pituitary macroadenoma: PRIMARYS post-hoc analysis","volume":"180","author":"Bonneville","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025100609562455800_lvaf194-B12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/cen.14946","article-title":"Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly","volume":"99","author":"Ruiz","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2025100609562455800_lvaf194-B13","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s40618-023-02299-7","article-title":"Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center","volume":"47","author":"Pirchio","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2025100609562455800_lvaf194-B14","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.3390\/cancers13123097","article-title":"Gender-specific efficacy revealed by head-to-head comparison of pasireotide and octreotide in a representative in vivo model of nonfunctioning pituitary tumors","volume":"13","author":"Gulde","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2025100609562455800_lvaf194-B15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1677\/ERC-06-0026","article-title":"Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion","volume":"14","author":"Zatelli","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"10","key":"2025100609562455800_lvaf194-B16","doi-asserted-by":"publisher","first-page":"EC-23-0155","DOI":"10.1530\/EC-23-0155","article-title":"Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly","volume":"12","author":"Marques","year":"2023","journal-title":"Endocr Connect"},{"issue":"3","key":"2025100609562455800_lvaf194-B17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11102-025-01514-3","article-title":"Pasireotide as first-line medical therapy for selected patients with acromegaly","volume":"28","author":"Olarescu","year":"2025","journal-title":"Pituitary"},{"issue":"10","key":"2025100609562455800_lvaf194-B18","doi-asserted-by":"publisher","first-page":"e0239021","DOI":"10.1371\/journal.pone.0239021","article-title":"Estimating the effect of a scanner upgrade on measures of grey matter structure for longitudinal designs","volume":"16","author":"Medawar","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"2025100609562455800_lvaf194-B19","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.3174\/ajnr.A4387","article-title":"Differentiation between cystic pituitary adenomas and Rathke cleft cysts: a diagnostic model using MRI","volume":"36","author":"Park","year":"2015","journal-title":"AJNR Am J Neuroradiol."}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf194\/64331633\/lvaf194.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/421\/64331633\/lvaf194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/4\/421\/64331633\/lvaf194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T13:56:29Z","timestamp":1759758989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/4\/421\/8259592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf194","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,20]]}}}